However, a clinical study using laser capture microdissection (LCM) and gene expression profiling in rectal carcinoma patients using bevacizumab (Genentech), an anti-VEGF antibody, found that CXCL12, CXCR4, and CXCL6/granulocyte chemoattractant protein-2/GCP-2 expression were induced in rectal cancer cells with bevacizumab administration, while neuropilin 1 was increased in TAMs (Xu et al., 2009). The gene discussed is CXCL6; the disease is rectal cancer.